Zobrazeno 1 - 5
of 5
pro vyhledávání: '"K H Costenbader"'
Autor:
S K Tedeschi, M Barbhaiya, J A Sparks, E W Karlson, L D Kubzansky, A L Roberts, W C Willett, B Lu, K H Costenbader
Supplemental material, LUP888791 Supplementary material for Dietary patterns and risk of systemic lupus erythematosus in women by S K Tedeschi, M Barbhaiya, J A Sparks, E W Karlson, L D Kubzansky, A L Roberts, W C Willett, B Lu and K H Costenbader in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a9f0c62144fca3bd7ff61406841c6a1
Autor:
V Chandran, N M Wulffraat, R C Kitridou, A Ramanan, P Geusens, R H Shmerling, L-S Tam, J Ahearn, A Marusic, R Burgos-Vargas, X Baraliakos, R Petty, E Naredo, P Youinou, I E van der Horst-Bruinsma, R Silver, F Wollheim, A Perl, B H Rovin, M Trojanowska, R Hirsch, J Merrill, R Luqmani, S Brown, A Kuhn, S Kamphuis, J T Watters, M Petri, J Braun, M Afj van de Laar, M A Becker, K H Costenbader, J Varga, H John, M Kaplan, P Woo, R Cervera, G S Hoffman, Y Shoenfeld, M Doherty, E. De Miguel, S Oliver, R Klocke, B Diamond, Fpjg Lafeber, J Hamburger, J Sieper, G Treharne, M Kloppenburg, M Ostensen, SC Mastbergen
Publikováno v:
Rheumatology. 51:i1-i14
Publikováno v:
Clinical and experimental rheumatology. 25(5)
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are common measures of systemic inflammation. Our goal was to identify clinical factors associated with CRP/ESR discordance.We identified patients with ESR and CRP results at our acade
Autor:
J F, Simard, K H, Costenbader
Publikováno v:
International journal of clinical practice. 61(7)
Systemic lupus erythematosus (SLE) is an often-severe autoimmune rheumatic disease most commonly diagnosed in women in their childbearing years. It is thought to develop when genetically predisposed individuals are exposed to one or more environmenta
Publikováno v:
International journal of clinical practice. 61(3)
Over the past decade, biological immunotherapy has revolutionised the treatment of rheumatoid arthritis (RA). The most widely used of these therapies targets tumour necrosis factor-alpha (TNF-alpha). Approximately 20% of patients fail to respond to T